Team Expansion

Dr. Devenport is Chief Operating Officer at GenrAb. Martin was formerly the COO at OncoC4, Inc. where he oversaw all operational activities, as well as business development, contracts and intellectual property. Prior to that Martin was Chief Operating Officer for OncoImmune, (acquired by Merck in 2020), and before that was VP for Business Strategy at Amplimmune Inc. In these roles, Martin has overseen numerous financings while being lead on strategic licensing and collaboration deals with large pharmaceutical partners. Martin is experienced with all aspects of the drug development process, including research, development, GMP manufacturing, regulatory and clinical trials, and has managed a number of biotechnology programs that reached clinical stage development in oncology and autoimmune indications.

Dr. Jonghee Han is a seasoned specialist in the field of neurological and inflammatory disorders with a robust foundation in biochemistry, cell and molecular biology, and preclinical animal studies. Prior to working at GenrAb, Jonghee was with Reata Pharmaceuticals where he played a pivotal role in the follow-up study of the FDA approved SKYCLARYS for Friedreich’s ataxia. Prior to Reata, Jonghee was an Instructor at UT Southwestern working on amyloid pathogenesis and lysosomal dysfunction in Alzheimer’s disease (AD), and the use of an anti-inflammatory drug using gamma-secretase hair follicle knockout mice with skin inflammation. Jonghee boasts an extensive track record of molecular engineering and cell-based assay screening, with a focus on small molecule drug discovery and innovative iPSCs-derived neuronal culture models, and a history of FDA-approved drug development and impactful peer-reviewed journal publications.